Loading stock data…
$1.34+0.04 (+3.08%)
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Dogwood Therapeutics, Inc. in the Healthcare sector is trading at $1.30 with a market capitalization of $57M. Wall Street consensus targets $14.00 (3 analysts), implying a +976.9% move over the next 12 months. The stock is currently near its 52-week low of $1.28, remaining 39.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.87M↑ | -$5.08M↓ | -$3.81M↑ | -$15.81M↓ | -$3.92M |
| Net Income | -$11.53M↓ | -$4.99M↓ | -$3.78M↑ | -$15.74M↓ | -$3.81M |
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has ...